MS and Demyelinating Disorders

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 1, 2020.

Educational sessions led by experts in multiple sclerosis will be held May 26-29, 2020.

Janssen’s S1P receptor modulator ponesimod showed its superiority to teriflunomide on annualized relapse rates, fatigue symptoms, MRI activity, brain atrophy, and NEDA-3 in patients with relapsing multiple sclerosis.

The professor of neurology at NYU Langone detailed the neurologic symptoms that have been observed in patients with COVID-19.

The neurologist at the Mellen Center for MS Treatment and Research at Cleveland Clinic spoke to the wide variety of clinical benefits observed with ofatumumab treatment and how it fits into the MS care landscape.

Novartis’s S1P receptor modulator siponimod (Mayzent) showed benefits in a number of patients with SPMS on the Motor Integration and Collateral subscales of the Expanded Disability Status Scale.

Vitalis’s VTS-Aspirin platform was granted an orphan drug designation to be used in combination with diroximel fumarate and monomethyl fumarate for the treatment of fumarate flush in relapsing multiple sclerosis.

The neurologist at the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the findings of a new pooled-data analysis of ofatumumab from the phase 3 ASCLEPIOS I and II trials.

The Rosenthal–Trotter MS Chair in Neuroimmunology at Washington University School of Medicine in St. Louis details why the COViMS registry can serve as an important instrument for clinicians who treat patients with multiple sclerosis.

Ofatumumab, Novartis’s fully human anti-CD20 monoclonal antibody, demonstrated a reduction in the risk of 3- and 6-month confirmed disability progression compared to teriflunomide in relapsing multiple sclerosis.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 24, 2020.

The drug's impact on neuroinflammation and neurodegeneration in the brain and spinal cord are currently being explored.

Five-year EXPAND study data suggest that Novartis’s S1P receptor modulator has sustained benefit and delays disability over long-term treatment in patients with SPMS.

The Group Medical Director of Neuroscience at Genentech discussed the shorter, 2-hour infusion time for ocrelizumab and how it might impact multiple sclerosis care as a whole.

Exclusive breastfeeding may be recommended after it was shown to reduce the risk of postpartum relapses.

The FDA has accepted an sBLA for a version of Genentech's ocrelizumab with a shorter administration time for the treatment of relapsing and primary progressive MS.

Neurology News Network for the week ending April 18, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 17, 2020.

In those with secondary progressive MS, evaluating diffusely abnormal white matter may provide a useful measure for therapies aiming to protect at-risk tissue, which may be able to slow progression.

The Processing Speed Test, a tech-enabled version of the SDMT, was shown to be significantly correlated with multiple measures in routine multiple sclerosis care.

The director of the Multiple Sclerosis Program at Cleveland Clinic Lou Ruvo Center for Brain Health discussed the correlation between age and disease duration in MS, as well as what was learned from a subanalysis of the EXPAND study of siponimod.

The probability of relapse and disability progression during pregnancy was associated with time when natalizumab was stopped and number of relapses in the year before natalizumab treatment.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 10, 2020.

The COViMs website includes FAQs, a sample Case Report Form, and COVID-19 esources and will provide real-time data on patients with multiple sclerosis and other central nervous system demyeliminating diseases who have developed COVID-19.

As the treatment of multiple sclerosis continues to evolve and improve, the proposition of lifetime therapy has come under scrutiny.